NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023
AUTHORS
Schaeffer
EM ,
Srinivas
S ,
Adra
N ,
An
Y ,
Barocas
D ,
Bitting
R ,
Bryce
A ,
Chapin
B ,
Cheng
HH ,
D'Amico
AV ,
Desai
N ,
Dorff
T ,
Eastham
JA ,
Farrington
TA ,
Gao
X ,
Gupta
S ,
Guzzo
T ,
Ippolito
JE ,
Kuettel
MR ,
Lang
JM ,
Lotan
T ,
McKay
RR ,
Morgan
T ,
Netto
G ,
Pow-Sang
JM ,
Reiter
R ,
Roach
M ,
Robin
T ,
Rosenfeld
S ,
Shabsigh
A ,
Spratt
D ,
Teply
BA ,
Tward
J ,
Valicenti
R ,
Wong
JK ,
Berardi
RA ,
Shead
DA ,
Freedman-Cass
DA ,
. Journal of the National Comprehensive Cancer Network : JNCCN. ; 20(12). 1288-1298
- PMID: 36509074 [PubMed].
ABSTRACT
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Tags: alumni publications 2022